Dong-A Socio Holdings Co., Ltd. (KRX:000640)

Market Cap	688.73B +12.5%
Revenue (ttm)	1.40T +9.0%
Net Income	107.66B +95.5%
EPS	16,237.55 +95.5%
Shares Out	6.63M
PE Ratio	6.40
Forward PE	8.37
Dividend	1,602.41 (1.54%)
Ex-Dividend Date	Mar 11, 2026

Volume	11,090
Average Volume	16,884
Open	104,100
Previous Close	104,000
Day's Range	103,150 - 104,900
52-Week Range	92,039 - 121,845
Beta	-0.06
RSI	44.33
Earnings Date	Apr 29, 2026

About Dong-A Socio Holdings

Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical tri...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 5,653
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000640

Financial Performance

In 2024, Dong-A Socio Holdings's revenue was 1.33 trillion, an increase of 17.78% compared to the previous year's 1.13 trillion. Earnings were 58.02 billion, an increase of 0.06%.